What's in Fondazione EMN Italy Onlus's pipeline?

Fondazione EMN Italy Onlus has 7 drugs in our index: 0 marketed, 0 filed, 4 in Phase 3, 2 in Phase 2, 1 in Phase 1.

Which companies overlap with Fondazione EMN Italy Onlus's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fondazione-emn-italy-onlus.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Fondazione EMN Italy Onlus — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fondazione EMN Italy Onlus pipeline: 0 marketed, 0 filed, 4 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Cyclophosphamide, Prednisone, Lenalidomide	Cyclophosphamide, Prednisone, Lenalidomide	phase 3	Combination chemotherapy and immunomodulatory therapy		Oncology
Bortezomib, Melphalan, Prednisone, Thalidomide	Bortezomib, Melphalan, Prednisone, Thalidomide	phase 3	Combination chemotherapy and immunomodulatory therapy	Proteasome (bortezomib), DNA (melphalan), glucocorticoid receptor (prednisone), cereblon (thalidomide)	Oncology
Melphalan, Prednisone, Lenalidomide	Melphalan, Prednisone, Lenalidomide	phase 3	Alkylating agent, Corticosteroid, Immunomodulatory drug		Oncology
Bortezomib, Melphalan, Prednisone	Bortezomib, Melphalan, Prednisone	phase 3	Proteasome inhibitor + alkylating agent + corticosteroid combination	20S proteasome (bortezomib); DNA (melphalan); glucocorticoid receptor (prednisone)	Oncology

Therapeutic area mix

Oncology · 4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Fondazione EMN Italy Onlus:

Cite this brief

Drug Landscape (2026). Fondazione EMN Italy Onlus — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fondazione-emn-italy-onlus. Accessed 2026-05-18.